Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab

Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscul...

Full description

Bibliographic Details
Main Authors: Huanyu Zhou, Xiaoxi Xie, Tianyu Zhang, Menghan Yang, Dong Zhou, Tianhua Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
autoimmune
cerebellum
encephalitis
toripalimab
irAE
anti-GAD65
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.850540/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.850540/full

Similar Items